- Philosophers on drugs.Bennett Holman - 2019 - Synthese 196 (11):4363-4390.details
|
|
The commercialization of the biomedical sciences: (mis)understanding bias.Inmaculada de Melo-Martín - 2019 - History and Philosophy of the Life Sciences 41 (3):34.details
|
|
Experimental Design: Ethics, Integrity and the Scientific Method.Jonathan Lewis - 2020 - In Ron Iphofen (ed.), Handbook of Research Ethics and Scientific Integrity. Springer. pp. 459-474.details
|
|
(1 other version)The Physician-Patient Relationship and a National Health Information Network.Leslie Pickering Francis - 2010 - Journal of Law, Medicine and Ethics 38 (1):36-49.details
|
|
(1 other version)Moral Psychology and the Intuition that Pharmaceutical Companies Have a ‘Special’ Obligation to Society.James M. Huebner - 2014 - Journal of Business Ethics 122 (3):501-510.details
|
|
(1 other version)Moral Psychology and the Intuition that Pharmaceutical Companies Have a ‘Special’ Obligation to Society.James M. Huebner - 2014 - Journal of Buisness Ethics (3):1-10.details
|
|
Eschewing Definitions of the Therapeutic Misconception: A Family Resemblance Analysis.D. S. Goldberg - 2011 - Journal of Medicine and Philosophy 36 (3):296-320.details
|
|
Clarifying conflict of interest.Howard Brody - 2011 - American Journal of Bioethics 11 (1):23 - 28.details
|
|
Responses to Peer Commentaries on “Clarifying Conflict of Interest”.Howard Brody - 2011 - American Journal of Bioethics 11 (1):W4 - W5.details
|
|
Huddle Gets It Right, Most Docs Don't.Paul H. Rubin - 2010 - American Journal of Bioethics 10 (1):17-19.details
|
|
A Duty to Participate in Research: Does Social Context Matter?Inmaculada de Melo-Martín - 2008 - American Journal of Bioethics 8 (10):28-36.details
|
|
(1 other version)More Regulation of Industry-Supported Biomedical Research: Are We Asking the Right Questions?Sigrid Fry-Revere & David Bjorn Malmstrom - 2009 - Journal of Law, Medicine and Ethics 37 (3):420-430.details
|
|
(1 other version)Drug Reps Off Campus! Promoting Professional Purity by Suppressing Commercial Speech.Lance K. Stell - 2009 - Journal of Law, Medicine and Ethics 37 (3):431-443.details
|
|
(1 other version)The Physician-Patient Relationship and a National Health Information Network.Leslie Pickering Francis - 2010 - Journal of Law, Medicine and Ethics 38 (1):36-49.details
|
|
Answering Brody's challenge from a pharmapologist perspective.Thomas D. Harter - 2011 - American Journal of Bioethics 11 (1):29 - 30.details
|
|
Moral Hazards Over Narrative Methods in Pediatrics? Not Worth the Risk.Kellie R. Lang & D. Micah Hester - 2016 - American Journal of Bioethics 16 (7):42-44.details
|
|
(1 other version)Pharmaceutical Industry Financial Support for Medical Education: Benefit, or Undue Influence?Howard Brody - 2009 - Journal of Law, Medicine and Ethics 37 (3):451-460.details
|
|
Financial Conflicts of Interest are of Higher Ethical Priority than “Intellectual” Conflicts of Interest.Daniel S. Goldberg - 2020 - Journal of Bioethical Inquiry 17 (2):217-227.details
|
|
Declarations, accusations and judgement: examining conflict of interest discourses as performative speech-acts.Christopher Mayes, Wendy Lipworth & Ian Kerridge - 2016 - Medicine, Health Care and Philosophy 19 (3):455-462.details
|
|
Drug Detailers, Professionalism, and Prudence.Howard Brody - 2010 - American Journal of Bioethics 10 (1):9-10.details
|
|
Misapplying Moral Hazard in Bioethics.Denis Arnold - 2016 - American Journal of Bioethics 16 (7):41-42.details
|
|
(1 other version)More Regulation of Industry-Supported Biomedical Research: Are We Asking the Right Questions?Sigrid Fry-Revere & David Bjorn Malmstrom - 2009 - Journal of Law, Medicine and Ethics 37 (3):420-430.details
|
|
Patenting and the Gender Gap: Should Women Be Encouraged to Patent More? [REVIEW]Inmaculada de Melo-Martín - 2013 - Science and Engineering Ethics 19 (2):491-504.details
|
|
Patenting and the Gender Gap: Should Women Be Encouraged to Patent More?Inmaculada Melo-Martín - 2013 - Science and Engineering Ethics 19 (2):491-504.details
|
|
Concussions, Professional Sports, and Conflicts of Interest: Why the National Football League’s Current Policies are Bad for Its Health. [REVIEW]Daniel S. Goldberg - 2008 - HEC Forum 20 (4):337-355.details
|
|
Progressive and degenerative journals: on the growth and appraisal of knowledge in scholarly publishing.Daniel J. Dunleavy - 2022 - European Journal for Philosophy of Science 12 (4):1-27.details
|
|
Pharmaceutical Sales Representatives in the United States and China: The Need for Professional Public Space.Xiaoying Chen - 2021 - Health Care Analysis 30 (1):35-56.details
|
|
Are Corporations Re-Defining Illness and Health? The Diabetes Epidemic, Goal Numbers, and Blockbuster Drugs.Linda M. Hunt, Elisabeth A. Arndt, Hannah S. Bell & Heather A. Howard - 2021 - Journal of Bioethical Inquiry 18 (3):477-497.details
|
|
On the fragility of medical virtue in a neoliberal context: the case of commercial conflicts of interest in reproductive medicine.Christopher Mayes, Brette Blakely, Ian Kerridge, Paul Komesaroff, Ian Olver & Wendy Lipworth - 2016 - Theoretical Medicine and Bioethics 37 (1):97-111.details
|
|
(1 other version)Pharmaceutical Industry Financial Support for Medical Education: Benefit, or Undue Influence?Howard Brody - 2009 - Journal of Law, Medicine and Ethics 37 (3):451-460.details
|
|
(1 other version)Better Regulation of Industry-Sponsored Clinical Trials is Long Overdue.Matthew Wynia & David Boren - 2009 - Journal of Law, Medicine and Ethics 37 (3):410-419.details
|
|
(1 other version)Better Regulation of Industry-Sponsored Clinical Trials Is Long Overdue.Matthew Wynia & David Boren - 2009 - Journal of Law, Medicine and Ethics 37 (3):410-419.details
|
|
What’s it to me? Self-interest and evaluations of financial conflicts of interest.Samuel V. Bruton & Donald F. Sacco - 2017 - Research Ethics 14 (4):1-17.details
|
|
A Christian Physician: Combining Conscience, Philanthropia, and Calling.Michael J. Sleasman & Gregory W. Rutecki - 2016 - Christian Bioethics 22 (3):340-362.details
|
|
Big Pharma: a former insider’s view. [REVIEW]David Badcott - 2013 - Medicine, Health Care and Philosophy 16 (2):249-264.details
|
|
Considerations for applying bioethics norms to a biopharmaceutical industry setting.Wendell Fortson, Kathleen Novak Stern, Curtis Chang, Angela Rossetti, Ariella Kelman, Michael Turik, Donald G. Therasse, Tatjana Poplazarova & Luann E. Van Campen - 2021 - BMC Medical Ethics 22 (1).details
|
|
Hidden Sources of Private Industry Funding.David B. Resnik - 2008 - American Journal of Bioethics 8 (8):60-61.details
|
|
The Details Are in the Field.Abraham P. Schwab - 2010 - American Journal of Bioethics 10 (1):19-21.details
|
|
The Pitfalls of Deducing Ethics From Behavioral Economics: Why the Association of American Medical Colleges Is Wrong About Pharmaceutical Detailing.Thomas S. Huddle - 2010 - American Journal of Bioethics 10 (1):1-8.details
|
|
Ask your doctor if this genetic test is right for you.Howard Brody - 2008 - American Journal of Bioethics 8 (6):1 – 2.details
|
|
(1 other version)Drug Reps off Campus! Promoting Professional Purity by Suppressing Commercial Speech.Lance K. Stell - 2009 - Journal of Law, Medicine and Ethics 37 (3):431-443.details
|
|